Brief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
28/09/2022 12:13
Sept 28 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX CONFIRMS FOCUS ON TREATMENT OF POST COVID-19
CONDITIONS
* RESVERLOGIX CORP - APABETALONE'S FUTURE CLINICAL
DEVELOPMENT
RELATED TO COVID-19 WILL FOCUS ON PREVENTION AND TREATMENT OF
POST COVID-19 CONDITIONS
* RESVERLOGIX CORP - FINALIZING PHASE 3 STUDY PROTOCOL OF
APABETALONE IN PCC AND PLANS TO LAUNCH TRIAL IN FIRST HALF OF
2023
Source text for Eikon: ID:nGNX4Bm949
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment